Azenta Life Sciences · 18 hours ago
Sr. Financial Analyst
Azenta Life Sciences is a global leader in the life sciences space, focused on innovation and customer-centric solutions. The Sr. Financial Analyst will support financial planning, reporting, and analysis activities, collaborating with cross-functional teams to drive data-informed decision-making and deliver accurate forecasts.
BiotechnologyClinical TrialsLife Science
Responsibilities
Lead budgeting, forecasting and long-range planning process across business units
Perform scenario analysis, identify opportunities for improvement, as well as risk assessment and mitigants
Develop and maintain complex financial models to support
Analyze monthly/quarterly financial results, identify trends, and provide variance explanations
Partner with cross-functional teams to evaluate business performance
Prepare review materials, reports and presentations to support senior leadership
Support ad hoc Corporate FP&A requirements
Annual planning process including the development of targets, timelines, templates and required deliverables and consolidation of the Annual Operating Plan
Preparation of executive presentations, including monthly operating reviews and analysis used for Board updates and investor presentations
Leading data, process, and reporting improvement initiatives; collaborate with Technology to automate and simplify
Qualification
Required
Bachelor's degree in Finance, Accounting, Economics, or related field
5+ years of progressive experience
Ability to prioritize assignments and be self-directed
Advanced proficiency in Excel and financial modeling
Strong systems orientation with experience in ERP (e.g., SAP, Oracle) and BI tools (e.g., Power BI, Tableau)
Solid communication skills
Strong attention to detail
Ability to analyze data to generate meaningful insights
Company
Azenta Life Sciences
Azenta Life Sciences provides life sciences solutions.
Funding
Current Stage
Public CompanyTotal Funding
$508.35MKey Investors
JP Morgan ChaseBrooks AutomationBroadOak Capital Partners
2022-11-23Post Ipo Equity· $500M
2021-12-01IPO
2014-03-12Series Unknown· $5.85M
Recent News
2025-12-10
Morningstar.com
2025-11-21
Company data provided by crunchbase